Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
A 44.81 0.74% 0.33
APLS closed up 0.74 percent on Friday, May 20, 2022, on approximately normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 200 DMA Bullish 0.00%
Doji - Bearish? Reversal 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
200 DMA Resistance Bearish 0.74%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.74%
20 DMA Support Bullish 0.74%
Inside Day Range Contraction 0.74%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Apellis Pharmaceuticals, Inc. Description

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Eye Organ Systems Inflammatory Diseases Macular Degeneration Related Macular Degeneration Pulmonary Disease Chronic Obstructive Pulmonary Disease Hemoglobin Autoimmune And Inflammatory Disease Complement System Treatment Of Chronic Obstructive Pulmonary Disease C3 Acquired Hemolytic Anemia Hemoglobinuria Intravitreal Administration Paroxysmal Nocturnal Hemoglobinuria Copd Intravitreal Injection Pnh

Is APLS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 73.0
52 Week Low 27.5
Average Volume 1,272,003
200-Day Moving Average 44.39
50-Day Moving Average 47.65
20-Day Moving Average 42.55
10-Day Moving Average 39.96
Average True Range 3.41
RSI 51.69
ADX 21.47
+DI 22.82
-DI 22.37
Chandelier Exit (Long, 3 ATRs) 43.08
Chandelier Exit (Short, 3 ATRs) 43.59
Upper Bollinger Bands 50.17
Lower Bollinger Band 34.92
Percent B (%b) 0.65
BandWidth 35.86
MACD Line -1.70
MACD Signal Line -2.40
MACD Histogram 0.7028
Fundamentals Value
Market Cap 3.39 Billion
Num Shares 75.6 Million
EPS -3.32
Price-to-Earnings (P/E) Ratio -13.49
Price-to-Sales 4846.49
Price-to-Book 33.50
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 49.59
Resistance 3 (R3) 49.39 47.60 48.79
Resistance 2 (R2) 47.60 46.38 47.70 48.53
Resistance 1 (R1) 46.21 45.63 45.31 46.40 48.26
Pivot Point 44.42 44.42 43.97 44.51 44.42
Support 1 (S1) 43.02 43.20 42.13 43.22 41.36
Support 2 (S2) 41.23 42.45 41.33 41.09
Support 3 (S3) 39.84 41.23 40.83
Support 4 (S4) 40.03